You are here: Industry Insights > RGX-314

News List

Regenxbio, AbbVie close license and collaboration deal to develop RGX-314 Pharmaceutical-Business-Review
November 11, 2021
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
REGENXBIO Doses First Patient in RGX-314 Trial for Diabetic Retinopathy americanpharmaceuticalreview
December 31, 2020
REGENXBIO announced the first patient has been dosed in ALTITUDE, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR).
REGENXBIO Announces Dosing of First Patient in Trial for Wet AMD Using Suprachoroidal Delivery americanpharmaceuticalreview
September 14, 2020
REGENXBIO announced the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (wet AMD).
Regenxbio Announces FDA Clearance of IND for Trial of Diabetic Retinopathy Treatment americanpharmaceuticalreview
August 26, 2020
Regenxbio announced the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR).